Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

344 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term effects of beta-blocker use on lung function in Japanese patients with chronic obstructive pulmonary disease.
Oda N, Miyahara N, Ichikawa H, Tanimoto Y, Kajimoto K, Sakugawa M, Kawai H, Taniguchi A, Morichika D, Tanimoto M, Kanehiro A, Kiura K. Oda N, et al. Among authors: kajimoto k. Int J Chron Obstruct Pulmon Dis. 2017 Apr 10;12:1119-1124. doi: 10.2147/COPD.S133071. eCollection 2017. Int J Chron Obstruct Pulmon Dis. 2017. PMID: 28435245 Free PMC article.
Deterioration of high-resolution computed tomography findings predicts disease progression after initial decline in forced vital capacity in idiopathic pulmonary fibrosis patients treated with pirfenidone.
Higo H, Miyahara N, Taniguchi A, Senoo S, Itano J, Watanabe H, Oda N, Kayatani H, Ichikawa H, Shibayama T, Kajimoto K, Tanimoto Y, Kanehiro A, Maeda Y, Kiura K; OKAYAMA respiratory disease study group (ORDSG). Higo H, et al. Among authors: kajimoto k. Respir Investig. 2020 May;58(3):185-189. doi: 10.1016/j.resinv.2019.12.007. Epub 2020 Feb 23. Respir Investig. 2020. PMID: 32102769 Free article.
Nintedanib can be used safely and effectively for idiopathic pulmonary fibrosis with predicted forced vital capacity ≤ 50%: A multi-center retrospective analysis.
Senoo S, Miyahara N, Taniguchi A, Oda N, Itano J, Higo H, Hara N, Watanabe H, Kano H, Suwaki T, Fuchimoto Y, Kajimoto K, Ichikawa H, Kudo K, Shibayama T, Tanimoto Y, Kuyama S, Kanehiro A, Maeda Y, Kiura K; Okayama Respiratory Disease Study Group (ORDSG). Senoo S, et al. Among authors: kajimoto k. PLoS One. 2020 Aug 27;15(8):e0236935. doi: 10.1371/journal.pone.0236935. eCollection 2020. PLoS One. 2020. PMID: 32853277 Free PMC article.
Pulmonary lymphangitic carcinomatosis secondary to ureteral cancer.
Sugimoto H, Sugimoto K, Inoue H, Tanaka R, Nakata K, Okino T, Kinoshita Y, Kajimoto K. Sugimoto H, et al. Among authors: kajimoto k. Respir Med Case Rep. 2021 Jan 19;32:101348. doi: 10.1016/j.rmcr.2021.101348. eCollection 2021. Respir Med Case Rep. 2021. PMID: 33532237 Free PMC article.
IgE-mediated allergic reaction in drug-induced asthma.
Kitani H, Kajimoto K, Sugimoto K, Mifune T, Mitsunobu F, Yokota S, Hiramatsu J, Kawaraya M, Tanizaki Y. Kitani H, et al. Among authors: kajimoto k. Acta Med Okayama. 1993 Oct;47(5):317-21. doi: 10.18926/AMO/31587. Acta Med Okayama. 1993. PMID: 7505995 Free article.
344 results